Operating cash flow was negative $32.9M in 2026Q3 and negative $82.8M in 2026Q1, implying free cash flow margins of -4.4% and -12.8% and suggesting that buybacks of $38.1M are being funded from balance sheet resources rather than internally generated cash.
Lakefront Biotherapeutics N.V. (LKFT) cash flow statement — 22-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 |
|---|
| Cash from Operations | -163.13M | -257.46M | - | - | -500.54M | -503.83M | -427.34M | 3.6B | -142.47M | -147.03M | 239.4M | -114.59M | -75.56M | 522K | 64.1M | -11.99M | -18.57M | 6.3M | -8.21M | 371K | -9.31M | -3.89M | -2.71M |
| Operating CF Margin % | - | -23.15% | - | - | -207.48% | -103.91% | -89.39% | 430.82% | -49.32% | -115.69% | 184.84% | -289.64% | -108.92% | 0.38% | 47.04% | -12.51% | -15.17% | 6.77% | -10.66% | 0.56% | -26.48% | -34.58% | -34.85% |
| Operating CF Growth % | 147.42% | - | - | - | 0.65% | -17.9% | -111.88% | 2624.74% | 3.1% | -161.42% | 308.92% | -51.66% | -14574.14% | -99.19% | 634.6% | 35.44% | -394.67% | 176.78% | -2312.67% | 103.98% | -139.52% | -43.43% | - |
| Net Income | 796.09M | 320.88M | - | - | -217.99M | -103.23M | -305.44M | 166.42M | -29.26M | -115.7M | 54.01M | -118.41M | 33.21M | -11.02M | -6.61M | -32.94M | 1.03M | 1.66M | -15.21M | -21.87M | -11.81M | -6.65M | -3.61M |
| Depreciation & Amortization | 3.04M | 55.88M | - | - | 65.57M | 34.64M | 18.68M | 12.1M | 5.08M | 4.29M | 4.18M | 3.4M | 4.65M | 8.15M | 9.01M | 12.1M | 11.63M | 6.96M | 7.37M | 8.35M | 4.73M | 1.31M | 1M |
| Stock-Based Compensation | 0 | 24M | - | - | 88.51M | 70.73M | 79.96M | 0 | 26.76M | 16.54M | 11.03M | 5.04M | 2.95M | 2.74M | 2.09M | 2.04M | 2.42M | 2.64M | 1.33M | 1.08M | 703K | 0 | 0 |
| Deferred Taxes | 0 | -18.14M | - | - | 2.84M | 2.42M | 2.12M | 0 | 50K | 198K | 235K | -1.22M | 2.34M | -2.95M | 1.71M | -2.2M | -224K | 1.35M | 6.52M | -82K | -4.5M | 0 | 0 |
| Other Non-Cash Items | -104.78M | 236.49M | - | - | -60M | -78M | 131.22M | 265.57M | -11.71M | 26.22M | -65.27M | 30.69M | -68.69M | 154K | -2K | 297K | -4.74M | -1.39M | 367K | 3.37M | -2.56M | -546K | -64K |
| Working Capital Changes | -851.89M | -876.57M | - | - | -379.47M | -430.38M | -353.88M | 3.15B | -133.39M | -78.56M | 235.21M | -34.09M | -50.02M | 3.44M | 57.91M | 8.71M | -28.69M | -4.92M | -8.58M | 9.51M | 4.13M | 1.99M | -41K |
| Change in Receivables | 0 | 86.59M | - | - | 68.98M | 79.86M | -177.16M | -75.28M | -76K | -27.66M | -12.98M | -7.22M | -10.11M | 1.07M | -16.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 28.85M | - | - | -34.59M | -21.17M | -100K | 22.38K | 3K | 22K | 25K | -44K | -32K | -39K | 291K | 942K | 344K | 1.26M | 502K | -1.45M | 293K | 943K | 51K |
| Change in Payables | 0 | 0 | - | - | 0 | 0 | 0 | 89.47M | 20M | 14.77M | 2.1M | -26.73M | 0 | 2.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 163.88M | 288.81M | - | - | -1.25B | 541.24M | 757.29M | -4.22B | -15.91M | -549K | -7.29M | -4.3M | 120.61M | -8.96M | -6.44M | 2.92M | -20.18M | -4.74M | -9.86M | -5.96M | -2.47M | -3.92M | -148K |
| Capital Expenditures | -1.88M | -13.7M | - | - | -27.39M | -54.2M | -42.52M | -51.13M | -13.72M | -7.44M | -4.79M | -6.67M | -2.8M | -7.87M | -6.84M | -5.83M | -4.25M | -5.19M | -5.7M | -6.04M | -4.27M | -1.11M | -148K |
| CapEx % of Revenue | 0.2% | 1.23% | - | - | 11.35% | 11.18% | 8.89% | 6.12% | 4.75% | 5.85% | 3.7% | 16.85% | 4.04% | 5.72% | 5.02% | 6.08% | 3.47% | 5.57% | 7.41% | 9.17% | 12.14% | 9.88% | 1.9% |
| Acquisitions | 3.51M | 19.43M | - | - | -115.27M | 28.7M | 0 | 0 | 3.33M | 7K | 0 | 110K | 130.79M | -1.15M | 0 | 8.71M | -15.96M | 0 | -857K | 0 | 1.8M | -2.81M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 7.82M | 40.76M | - | - | -15.82M | -3.66M | -45.24M | 0 | -3.32M | 6.52M | 253K | 2.37M | -7.38M | 65K | 399K | 44K | 35K | 443K | -3.3M | 80K | 0 | 0 | 0 |
| Cash from Financing | -39.54M | -3.27M | - | - | -1.49M | -3.88M | 22.04M | 1.5B | 287.88M | 353.36M | 396M | 271.37M | 4.21M | 55.82M | 4.03M | 633K | 31.16M | 18.52M | -3.92M | 3.4M | 39.77M | 21.16M | 96K |
| Debt Issued (Net) | -915K | -3.27M | - | - | -8.18M | -7.19M | -6.25M | -5.7M | -5K | -65K | -49K | -43K | -216K | -308K | -477K | -343K | -255K | -497K | -5.08M | -2.51M | -1.55M | -351K | -106K |
| Equity Issued (Net) | -38.06M | 0 | - | - | 0 | 0 | 0 | 1.5B | 296.19M | 363.92M | 392.12M | 278.7M | 0 | 54.8M | 2.74M | 553K | 0 | 0 | 0 | 0 | 40.95M | 21.14M | 0 |
| Dividends Paid | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -38.06M | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -558.73K | 0 | - | - | 6.7M | 3.31M | 28.29M | 0 | -8.31M | -10.5M | 3.92M | -7.29M | 4.43M | 0 | 0 | 423K | 31.41M | 18.65M | 1.16M | 5.91M | 0 | 368K | 202K |
| Net Change in Cash | -105.86M | 23.63M | - | - | -1.73B | 90.3M | 281.45M | 382.13M | 139.59M | 177.97M | 632.93M | 152.6M | 49.54M | 46.83M | 62.09M | -7.84M | -6.99M | 20.07M | -21.98M | -2.22M | 27.9M | 13.34M | -2.76M |
| Free Cash Flow | -165.01M | -271.31M | - | - | -537.49M | -561.71M | -518.65M | 3.57B | -156.18M | -154.47M | 234.61M | -121.25M | -78.36M | -7.35M | 57.27M | -17.82M | -22.83M | 1.12M | -13.91M | -5.67M | -13.58M | -5M | -2.86M |
| FCF Margin % | -17.8% | -24.39% | - | - | -222.8% | -115.85% | -108.49% | 427.82% | -54.07% | -121.54% | 181.14% | -306.49% | -112.96% | -5.34% | 42.03% | -18.59% | -18.65% | 1.2% | -18.07% | -8.61% | -38.62% | -44.47% | -36.75% |
| FCF Growth % | - | - | - | - | 4.31% | -8.3% | -114.52% | 2386.96% | -1.11% | -165.84% | 293.49% | -54.74% | -965.96% | -112.84% | 421.3% | 21.91% | -2143.51% | 108.03% | -145.17% | 58.21% | -171.63% | -74.88% | - |
| FCF per Share | -2.51 | -4.12 | - | - | -8.18 | -8.58 | -7.97 | 62.00 | -3.00 | -3.12 | 5.13 | -3.40 | -2.60 | -0.26 | 2.16 | -0.68 | -0.94 | 0.05 | -0.66 | -0.27 | -1.00 | -0.56 | -0.48 |
| FCF Conversion (FCF/Net Income) | -0.21x | -0.80x | - | - | 2.30x | 4.02x | 1.40x | 24.00x | 4.87x | 1.27x | 4.43x | 0.97x | -2.27x | -0.06x | -11.21x | 0.36x | -4.25x | 2.09x | 0.56x | -0.02x | 0.82x | 0.59x | 0.76x |
| Interest Paid | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LKFT stock.
Lakefront Biotherapeutics N.V. (LKFT) generated $-257.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Lakefront Biotherapeutics N.V. (LKFT) reported negative free cash flow of $271.3M in 2025, indicating capital requirements exceeded cash from operations.
Lakefront Biotherapeutics N.V. (LKFT) spent $13.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Earnings Disconnected From Operating Cash
According to reported quarterly figures, LKFT's operating cash flow ran negative in most recent quarters, with 2026Q1 operating cash outflow of $82.8M against net income of $14.5M, a gap that suggests reported profits are not converting to cash.
The 2026Q1 operating cash flow ratio of -5.71 against positive net income indicates that the earnings figure is not being supported by underlying cash generation. The 2025Q4 net income of $782.1M alongside operating cash outflow of $47.5M further suggests the reported profit is driven by non-cash or non-operating items rather than core business activity. Investors should monitor whether future operating cash flow turns positive, as the current pattern warrants further investigation into earnings quality.
Free Cash Flow Remains Deeply Negative
Based on reported figures, LKFT's free cash flow margin was -12.8% in 2026Q1 and -173.0% in 2025Q2, with free cash outflows of $82.9M and $112.9M respectively, showing no sustained move toward self-funding.
The free cash flow margins across the reported quarters appear volatile and predominantly negative, with the two most recent quarters showing outflows of $33.1M in 2026Q3 and $82.9M in 2026Q1. The absence of any positive free cash flow quarter in the supplied window suggests the business has not yet reached a point where operations fund its own investment. This pattern may indicate continued dependence on external capital, though the supplied data does not disclose financing sources.
Minimal Capital Intensity Relative to Burn
As reported in financial statements, LKFT's capital expenditure ran at 0.2% to 6.4% of revenue, with the largest CapEx of $4.2M in 2025Q2, indicating that cash burn is driven by operations rather than physical asset investment.
The low capital intensity implies that LKFT's cash consumption is not primarily a function of infrastructure build-out, which shifts scrutiny toward operating expenses and working capital. Given the CapEx figures are small relative to operating outflows, the capital spending profile does not explain the scale of the cash deficit. Investors may wish to examine the operating cost base and research spending as the primary cash drivers.
Working Capital Swings Dominate Quarterly Results
Based on LKFT's reported figures, working capital changes ranged from a $813.8M outflow in 2025Q4 to a $2.7M outflow in 2026Q3, indicating that balance sheet timing drives much of the quarterly cash variance.
The magnitude of the 2025Q4 working capital outflow of $813.8M, set against the $782.1M net income in the same quarter, suggests that reported earnings and cash timing are heavily misaligned. Such large swings may reflect revenue recognition timing or receivable and payable movements rather than sustainable operating performance. The pattern warrants further investigation into the components of working capital before inferring any underlying efficiency trend.
Buybacks Continue Despite Cash Outflows
According to recent reported figures, LKFT deployed $38.1M into share repurchases in 2026Q3 while operating cash flow was negative $32.9M, a pattern that appears to draw on balance sheet resources rather than internally generated cash.
Repurchasing shares while the business is burning operating cash raises a question about the funding source and the capital allocation priority. The supplied data does not disclose the cash balance or financing arrangements, so the sustainability of this deployment cannot be confirmed. Investors should monitor whether buybacks persist once cash reserves are tested by continued operating outflows.
Reported Profit Spike Obscures Recurring Cash Losses
As reported in the filings, the $782.1M net income in 2025Q4 coincided with $47.5M of operating cash outflow, suggesting the headline profit may rest on a single non-recurring item rather than a durable change in the cash profile.
If the 2025Q4 earnings spike is non-recurring, the more representative picture is the surrounding quarters, where operating cash outflows persisted without offsetting profit. The counter-argument to a Burning classification would require evidence that the spike reflects sustainable operating conversion, which the supplied cash flow figures do not show. Investors should weigh the cumulative cash burn across the ten-quarter window rather than any single quarter's reported earnings.